Table 5.
Comparison of ovarian response and laboratory and pregnancy results between studies in the literature for women sero-positive to HCV
| Authors and year of study | Shaw-Jackson et al.2016b | Hanafi et al. [15]c | Englert et al. [16]d | Yang et al. [18]e | Prisant et al. [17]f | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients sero-positive for HCV with an unknown or negative RT-PCR resulta | |||||||||||||||
| Ovarian response | |||||||||||||||
| Cycles | 37 | 111 | P | 40 | 40 | P | 42 | 84 | P | 90 | 1256 | P | 45 | 45 | P |
| HCV | controls | value | HCV | controls | value | HCV | controls | value | HCV | controls | value | HCV | controls | value | |
| Cycle cancelation | 63% | 77% | 0.52 | 30% | 5% | 0.0001 | 10 | 5 | <0.01 | – | – | – | – | – | – |
| Dose FSH | – | – | – | 28.4 ± 4.6 | 26.1 ± 6.54 | NS | 3610 ± 1563 | 2968 ± 1379 | 0.03 | 2025 | 2625 | 0.269 | – | – | – |
| Length stim | – | – | – | 12.5 ± 1.1 | 12.0 ± 1.5 | ≤0.05 | 11.7 ± 2.4 | 11.5 ± 2.5 | ≥0.05 | 10 | 11 | 0.181 | – | – | – |
| Estradiol max | 1428 | 1620 | 0.27 | 2890 ± 1586 | 4670 ± 1693 | ≤0.05 | 2496 ± 1221 | 2929 ± 1300 | ≥0.05 | – | – | – | – | – | – |
| Oocytes collected | 6.5 | 6.0 | 0.43 | 9.4 ± 4.2 | 12.0 ± 5.2 | ≤0.05 | 9.4 ± 4.7 | 11.3 ± 6.7 | ≥0.05 | 84% | 85% | 0.205 | 5.6 ± 4.9 | 6.0 ± 4.4 | >0.05 |
| P significance | <0.05 | ≤0.05 | – | <0.05 | NS | ||||||||||
| Laboratory and pregnancy results | |||||||||||||||
| Cycles | 25 | 25 | P | 28 | 38 | P | 31 | 78 | P | 90 | 1256 | P | 37 | 42 | P |
| HCV | controls | value | HCV | controls | value | HCV | controls | value | HCV | controls | value | HCV | controls | value | |
| Fertilization rate | 67% | 86% | 0.04 | 32% | 67% | 0.0035 | 56% | 59% | ≥0.05 | 77% | 78% | 0.413 | 71% | 70% | >0.05 |
| Embryo quality | 56% | 48% | 0.36 | 62% | 61% | >0.05 | 2.9 ± 1.3 | 3.1 ± 1.0 | ≥0.05 | 67% | 71% | 0.649 | – | – | – |
| Implantation rate | 6% | 23% | 0.04 | 45% | 52% | NS | 19% | 19% | ≥0.05 | – | – | – | 5% | 10% | >0.05 |
| Pregnancy rate | 12% | 36% | 0.10 | 33% | 48% | >0.05 | 19% | 26% | ≥0.05 | 46% | 55% | 0.138 | 11% | 13% | >0.05 |
| Live births | 2 | 7 | – | 11 | 15 | NS | – | – | – | – | – | – | 2 | 4 | >0.05 |
| P significance | <0.05 | ≤0.05 | <0.05 | NS | ≤0.05 | ||||||||||
Results are presented as percentages, values or mean values ± standard deviation or otherwise specified. P values are provided from individual studies with their level of significance. Length stim length of stimulation (days); Estradiol max the peak value during stimulation; NS not specified.
a All studies were for sero-positive patients with an unknown status for viral replication except for the study of Hanafi et al., where RT-PCR was negative. For the study of Yang et al., the majority of patients were also confirmed to be RT-PCR negative (personal communication).
bCycle cancelation is calculated as the percentage of cancelations due to poor response. Estradiol max, oocytes collected, and fertilization rates are presented as median values without min-max due to lack of space. Embryo quality is assessed for transferred embryos. Clinical pregnancy rates are calculated per transfer
cCycle cancelation is calculated for women with no mature oocytes at retrieval. FSH dose is calculated as the number of ampoules. Clinical pregnancy rates are calculated per cycle
dIn this study, 42 cycles are analyzed without the number of patients being specified
eFSH dose and stimulation length are provided as median values without min-max due to lack of space. Oocytes collected are calculated as percentage of oocytes retrieved. Clinical pregnancy rate is the ratio between the number of pregnancies and the number of periodicities
f22 HCV positive women and 42 control women with 45 oocyte retrievals in both cases were included. Clinical pregnancy rates are calculated per transfer